Eloralintide Safety Certified Peptide Manufacturers Wholesale Price 99% Purity
TDS 58 Inquiries
2883634-40-8
Research Grade
99.9%
GUANGZHOU
HF
5mg/vial
2027-03-26
peptides
-
Product Description
-
Seller Information
-
Inquiry History
-
DescriptionECHEMI Editorial Reference
Eloralintide (CAS No. 2883634-40-8) is a long-acting amylin analog and peptide-based pharmaceutical ingredient. Its modified peptide structure features a methylene thioacetal bridge and a C20 fatty diacid side chain, contributing to its distinctive molecular and physicochemical properties. As a peptide pharmaceutical raw material, Eloralintide is suitable for API research, analytical studies, and pharmaceutical development.
CertificatesBasic Info-
Product Name:
Eloralintide
Other Name:Eloralintide;AMY1176;LY3841136;Eloralintide,LY3841136
CAS No.:2883634-40-8
Molecular Weight:0
EC Number:262-076-3
Color/Form:White to off-white
Categories:
Research-
Class:
Amylin receptor (AMYR) agonist (peptide, long-acting)
Status:Investigational — Phase 1/2 (T2DM and obesity)
Mechanism:Eloralintide is an amylin receptor agonist developed by Eli Lilly for type 2 diabetes and obesity. It activates the amylin receptor (AMYR), reducing food intake, delaying gastric emptying, and promoting satiety. It is structurally distinct from cagrilintide (Novo Nordisk). Being explored as monotherapy and in combination with GLP-1R agonists.
Activity note:Limited public data. Eloralintide is in early clinical development; specific EC50 values have not been publicly disclosed.
Source:MCE: Eloralintide (CAS 2883634-40-8); AbMole product data sheet.
References-
PubChem:Disclaimer:
Eloralintide is NOT FDA-approved or EMA-approved. It is in Phase 1/2 clinical development by Eli Lilly. This listing is for industrial and laboratory research use only. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
peptides
-
Location:
No. 85, Qingnian Road, Hongqiao District, Tianjin
-
Total Annual Revenue:
$5 million-$10 million
-
Total Employees:
51-100
-
Year of Establishment:
2026
-
-
Inquiry History58 Inquiries
Country Product Purchase Quantity Date Posted
United States
Eloralintide
1 KG May 28, 2026
Philippines
Eloralintide
100 PCS Sep 4, 2026
Germany
Eloralintide
200 MG Sep 1, 2026
United States
Eloralintide
10 MT Aug 24, 2026
Philippines
eloralintide
10 MT Aug 22, 2026
Philippines
Eloralintide
1 G Aug 21, 2026
United States
Eloralintide
5 MT Aug 10, 2026
United States
Eloralintide
10 MG Aug 3, 2026
United States
eloralintide
1 PCS Jul 26, 2026
Australia
Eloralintide
15 MG Jul 20, 2026
United States
Eloralintide
1 MT Jul 15, 2026
United States
Eloralintide
20 MG Jul 13, 2026
United States
Eloralintide
1 Jul 4, 2026
United States
Eloralintide
100 MT Jun 29, 2026
United States
Elorintide
15 MG Jun 15, 2026
United States
(LY3841136)
1000 MG Jun 8, 2026
Australia
Eloralintide
100 MT May 8, 2026
Thailand
Eloralintide
2 G Mar 30, 2026
United States
Eloralintide
3 Mar 9, 2026
United States
Eloralintide
2 G Feb 7, 2026 Post an enquiry for this product
